These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36622786)

  • 1. Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.
    Green C; McGinley J; Sande C; Capone S; Makvandi-Nejad S; Vitelli A; Silva-Reyes L; Bibi S; Otasowie C; Sheerin D; Thompson A; Dold C; Klenerman P; Barnes E; Dorrell L; Rollier C; Pollard A; O'Connor D
    Clin Exp Immunol; 2023 Mar; 211(3):269-279. PubMed ID: 36622786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
    Green CA; Scarselli E; Sande CJ; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Del Sorbo M; Angus B; Siani L; Di Marco S; Traboni C; Folgori A; Colloca S; Capone S; Vitelli A; Cortese R; Klenerman P; Nicosia A; Pollard AJ
    Sci Transl Med; 2015 Aug; 7(300):300ra126. PubMed ID: 26268313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
    Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
    J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.
    Green CA; Scarselli E; Voysey M; Capone S; Vitelli A; Nicosia A; Cortese R; Thompson AJ; Sande CS; de Lara C; Klenerman P; Pollard AJ
    BMJ Open; 2015 Oct; 5(10):e008748. PubMed ID: 26510727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
    Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
    Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice.
    Li X; Wang L; Liu J; Fang E; Liu X; Peng Q; Zhang Z; Li M; Liu X; Wu X; Zhao D; Yang L; Li J; Cao S; Huang Y; Shi L; Xu H; Wang Y; Suo Y; Yue G; Nie J; Huang W; Li W; Li Y
    Emerg Microbes Infect; 2022 Dec; 11(1):1890-1899. PubMed ID: 35775819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates.
    Pierantoni A; Esposito ML; Ammendola V; Napolitano F; Grazioli F; Abbate A; Del Sorbo M; Siani L; D'Alise AM; Taglioni A; Perretta G; Siccardi A; Soprana E; Panigada M; Thom M; Scarselli E; Folgori A; Colloca S; Taylor G; Cortese R; Nicosia A; Capone S; Vitelli A
    Mol Ther Methods Clin Dev; 2015; 2():15018. PubMed ID: 26015988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
    Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
    J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
    Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
    Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections.
    Taylor G; Thom M; Capone S; Pierantoni A; Guzman E; Herbert R; Scarselli E; Napolitano F; Giuliani A; Folgori A; Colloca S; Cortese R; Nicosia A; Vitelli A
    Sci Transl Med; 2015 Aug; 7(300):300ra127. PubMed ID: 26268314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
    Zhu F; Jin P; Zhu T; Wang W; Ye H; Pan H; Hou L; Li J; Wang X; Wu S; Wang Y; Gou J; Huang H; Wu H; Wang X; Chen W
    Clin Infect Dis; 2022 Aug; 75(1):e783-e791. PubMed ID: 34551104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
    Hamer MJ; Houser KV; Hofstetter AR; Ortega-Villa AM; Lee C; Preston A; Augustine B; Andrews C; Yamshchikov GV; Hickman S; Schech S; Hutter JN; Scott PT; Waterman PE; Amare MF; Kioko V; Storme C; Modjarrad K; McCauley MD; Robb ML; Gaudinski MR; Gordon IJ; Holman LA; Widge AT; Strom L; Happe M; Cox JH; Vazquez S; Stanley DA; Murray T; Dulan CNM; Hunegnaw R; Narpala SR; Swanson PA; Basappa M; Thillainathan J; Padilla M; Flach B; O'Connell S; Trofymenko O; Morgan P; Coates EE; Gall JG; McDermott AB; Koup RA; Mascola JR; Ploquin A; Sullivan NJ; Ake JA; Ledgerwood JE;
    Lancet; 2023 Jan; 401(10373):294-302. PubMed ID: 36709074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
    Cicconi P; Jones C; Sarkar E; Silva-Reyes L; Klenerman P; de Lara C; Hutchings C; Moris P; Janssens M; Fissette LA; Picciolato M; Leach A; Gonzalez-Lopez A; Dieussaert I; Snape MD
    Clin Infect Dis; 2020 May; 70(10):2073-2081. PubMed ID: 31340042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA.
    Ewer K; Rampling T; Venkatraman N; Bowyer G; Wright D; Lambe T; Imoukhuede EB; Payne R; Fehling SK; Strecker T; Biedenkopf N; Krähling V; Tully CM; Edwards NJ; Bentley EM; Samuel D; Labbé G; Jin J; Gibani M; Minhinnick A; Wilkie M; Poulton I; Lella N; Roberts R; Hartnell F; Bliss C; Sierra-Davidson K; Powlson J; Berrie E; Tedder R; Roman F; De Ryck I; Nicosia A; Sullivan NJ; Stanley DA; Mbaya OT; Ledgerwood JE; Schwartz RM; Siani L; Colloca S; Folgori A; Di Marco S; Cortese R; Wright E; Becker S; Graham BS; Koup RA; Levine MM; Volkmann A; Chaplin P; Pollard AJ; Draper SJ; Ballou WR; Lawrie A; Gilbert SC; Hill AV
    N Engl J Med; 2016 Apr; 374(17):1635-46. PubMed ID: 25629663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice.
    Cervantes-Torres J; Cabello-Gutiérrez C; Ayón-Núñez DA; Soldevila G; Olguin-Alor R; Diaz G; Acero G; Segura-Velázquez R; Huerta L; Gracia-Mora I; Cobos L; Pérez-Tapia M; Almagro JC; Suárez-Güemes F; Bobes RJ; Fragoso G; Sciutto E; Laclette JP
    Appl Microbiol Biotechnol; 2024 Jan; 108(1):179. PubMed ID: 38280035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
    Hartnell F; Brown A; Capone S; Kopycinski J; Bliss C; Makvandi-Nejad S; Swadling L; Ghaffari E; Cicconi P; Del Sorbo M; Sbrocchi R; Esposito I; Vassilev V; Marriott P; Gardiner CM; Bannan C; Bergin C; Hoffmann M; Turner B; Nicosia A; Folgori A; Hanke T; Barnes E; Dorrell L
    Front Immunol; 2018; 9():3175. PubMed ID: 30713538
    [No Abstract]   [Full Text] [Related]  

  • 20. Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.
    Xing Z; McFarland CT; Sallenave JM; Izzo A; Wang J; McMurray DN
    PLoS One; 2009 Jun; 4(6):e5856. PubMed ID: 19516906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.